C. Markopoulos
National and Kapodistrian University of Athens, Surgery, Faculty Member
- Christos J. Markopoulos is Professor of Surgery, Athens University Medical School and directorof the Breast Unit at ‘Laiko’ University Hospital of Athens, and Athens Medical Centre, Greece. He qualified from Athens University Medical School in 1979 and he specialized in general surgery (1985). He received his PhD from Athens University, Greece, in 1985 an... moreChristos J. Markopoulos is Professor of Surgery, Athens University Medical School and directorof the Breast Unit at ‘Laiko’ University Hospital of Athens, and Athens Medical Centre, Greece.
He qualified from Athens University Medical School in 1979 and he specialized in general surgery (1985). He received his PhD from Athens University, Greece, in 1985 and his MPhil degree in oncology–breast cancer from University of London, United Kingdom, in 1988.
He specialized in breast cancer management working as senior registrar in surgery at the Breast Unit of St George’s Hospital and Medical School and at The Royal Marsden Hospital in London (1985-1988).
He has also been research fellow at Ludwing Institute for Cancer Research at Sutton, United Kingdom.
Professor Markopoulos has published over 300 scientific papers in international and Greek medical journals having over 4,000 citations and has also authored several books on breast disease. He is a member of several medical associations and societies including the British Association of Surgical Oncology (BASO), Association of Breast Surgery at The Royal College of Surgeons (ABS), American College of Breast Surgeons (ACBS), European Society of Surgical Oncology (ESSO).
He is President of UEMS – EBS - Division of Breast Surgery and Head of the Examination Board for the EBSQ in Breast Surgery.
In 2000, he founded "The Hellenic Society of Breast Surgeons - HSBS" (President 2000-2015) and he is responsible of the education, training and clinical trials section of the society. He is the responsible professor of the elective course on Breast Disease for the final year students of Athens University Medical School. He is national coordinator for various international trials and president or member of the scientific committees of Greek breast cancer advocacy groups and Europa Donna Hellas. Professor Markopoulos has organized a large number of national and international postgraduate courses and meetings on breast cancer over the last 20 years and he has lectured extensively as an invited speaker at national and international congresses.edit
This phase II trial studied the efficacy and toxicity of docetaxel-epirubicin, supported by granulocyte colony-stimulating factor, as first-line chemotherapy in metastatic breast cancer. Patients received epirubicin (60 mg/m2) followed 1... more
This phase II trial studied the efficacy and toxicity of docetaxel-epirubicin, supported by granulocyte colony-stimulating factor, as first-line chemotherapy in metastatic breast cancer. Patients received epirubicin (60 mg/m2) followed 1 hour later by docetaxel (80 mg/m2) every 3 weeks for a maximum of 8 cycles or until disease progression. Prophylactic granulocyte colony-stimulating factor (5 micrograms/kg) was administered daily for 5 days. Sixty-nine patients were evaluable for efficacy and toxicity. Objective responses occurred in 45 patients (65%; 95% confidence interval: 53-76%), with 11 (16%) complete responses and 34 (49%) partial responses. Responses were observed at all metastatic sites. The median response duration was 8 months (range 4-68), median time to progression was 10 months (range 4-68) and median overall survival was 24 months (range 7-68): neutropenia was dose limiting (46% grade 3-4 toxicity). The left ventricular ejection, fraction measured in 50 patients, fel...